Pharmaceutical Company
Bio-pharmaceutical drugs & drug development programs; particularly those designed to treat rare diseases, such as Orphan Drug Act Incentives, including the Orphan Drug Tax Credit. Issues generally related to:  bio-pharmaceutical drugs and drug development programs, including but not limited to Orphan Drug Act incentives, the 340B program, drug pricing proposals, access to rare disease and gene therapy drugs, newborn screening and gene panel screening, and FDA approvals of drugs designed to treat rare diseases. Issues generally related to:  bio-pharmaceutical drugs and drug development programs, including but not limited to the 340B program, drug pricing proposals, Medicaid payments to providers, and access to rare disease and gene therapy drugs.
TAX - Taxation/Internal Revenue Code HCR - Health Issues MMM - Medicare/Medicaid
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
CHAMBER HILL STRATEGIES
3325 N Kensington Street, Arlington, VA, 22207, US
MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ANNA KATHERINE WEINSTEIN MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ANNA KATHERINE WEINSTEIN MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ANNA KATHERINE WEINSTEIN
Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce